{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:32:45Z","timestamp":1790386365263,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ijtb.2023.04.006","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T10:55:53Z","timestamp":1681124153000},"page":"S101-S109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S1","title":["Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0084-839X","authenticated-orcid":false,"given":"Gyanshankar","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Munje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Khateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2023.04.006_bib1","series-title":"Global Tuberculosis Report 2022","year":"2022"},{"issue":"suppl_3","key":"10.1016\/j.ijtb.2023.04.006_bib2","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/cid\/ciy625","article-title":"Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment","volume":"67","author":"Bolhuis","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ijtb.2023.04.006_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4103\/1995-7645.329004","article-title":"Nix-TB and ZeNix trials: paving the way for shorter regimens for drug-resistant tuberculosis","volume":"14","author":"Mishra","year":"2021","journal-title":"Asian Pac J Tropical Med"},{"key":"10.1016\/j.ijtb.2023.04.006_bib4","series-title":"Guidelines for Programmatic Management of Drug Resistant Tuberculosis in India 2021 [Internet]","first-page":"1","year":"2021"},{"key":"10.1016\/j.ijtb.2023.04.006_bib5","series-title":"Ready Reckoner for Medical Officers: Adverse Drug Reactions Associated with Ready Reckoner for Medical Officers, Identification & Management Anti-Tubercular Drugs [Internet]","year":"2020"},{"issue":"2","key":"10.1016\/j.ijtb.2023.04.006_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijtb.2023.04.006_bib7","first-page":"1","year":"2020"},{"issue":"12","key":"10.1016\/j.ijtb.2023.04.006_bib8","article-title":"Linezolid\u00a0population pharmacokinetics in South African adults with drug-resistant tuberculosis","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob Agents Chemother [Internet]"},{"key":"10.1016\/j.ijtb.2023.04.006_bib9","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2147\/IDR.S365371","article-title":"Linezolid-associated neuropathy in patients with MDR\/XDR tuberculosis in shenzhen, China","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect Drug Resist [Internet]"},{"issue":"4","key":"10.1016\/j.ijtb.2023.04.006_bib10","first-page":"347","article-title":"Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis","volume":"7","author":"Shin","year":"2003","journal-title":"Int J Tubercul Lung Dis"},{"issue":"6","key":"10.1016\/j.ijtb.2023.04.006_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5588\/ijtld.22.0188","article-title":"Clinical standards for the dosing and management of TB drugs","volume":"26","author":"Alffenaar","year":"2022","journal-title":"Int J Tubercul Lung Dis"},{"issue":"7","key":"10.1016\/j.ijtb.2023.04.006_bib12","first-page":"1","article-title":"Common and rare hematological manifestations and adverse drug events during treatment of active TB: a state of art","volume":"9","author":"Minardi","year":"2021","journal-title":"Microorganisms [Internet]"},{"issue":"1","key":"10.1016\/j.ijtb.2023.04.006_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.31688\/ABMU.2020.55.1.13","article-title":"Changes of vitamins B1, B12 as predictors of peripheral polyneuropathy in pulmonary tuberculosis patients","volume":"55","author":"Shvets","year":"2020","journal-title":"Arch Balk Med Union"},{"issue":"SEP","key":"10.1016\/j.ijtb.2023.04.006_bib13","first-page":"325","article-title":"Linezolid toxicity and mitochondrial susceptibility: a novel neurological complication in a Lebanese patient","volume":"7","author":"Abou Hassan","year":"2016","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ijtb.2023.04.006_bib14","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.5588\/ijtld.16.0113","article-title":"Evolving strategies for dose optimization of linezolid for treatment of tuberculosis","volume":"20","author":"Nuermberger","year":"2016","journal-title":"Int J Tubercul Lung Dis"},{"issue":"1","key":"10.1016\/j.ijtb.2023.04.006_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2023.04.006_bib16","article-title":"Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013\u20132018","volume":"22","author":"McDowell","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"8","key":"10.1016\/j.ijtb.2023.04.006_bib17","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis [Internet]"},{"issue":"4","key":"10.1016\/j.ijtb.2023.04.006_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.5588\/ijtld.19.0444","article-title":"Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study","volume":"24","author":"Mikiashvili","year":"2020","journal-title":"Int J Tubercul Lung Dis"},{"issue":"36","key":"10.1016\/j.ijtb.2023.04.006_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012114","article-title":"The risk factors of linezolid-induced lactic acidosis: a case report and review","volume":"97","author":"Mao","year":"2018","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.ijtb.2023.04.006_bib20","article-title":"Linezolid-associated optic neuropathy in drug-resistant tuberculosis patients in Mumbai, India","volume":"11","author":"Mehta","year":"2016","journal-title":"PLoS One [Internet]"},{"issue":"8","key":"10.1016\/j.ijtb.2023.04.006_bib21","first-page":"OCD14","article-title":"Adverse drug reactions to a daily fixed-dose combination based anti-tuberculosis treatment regime in India' s national tuberculosis elimination programme : a prospective cohort study","volume":"16","author":"Mate","year":"2022","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"10.1016\/j.ijtb.2023.04.006_bib22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1515\/jbcpp-2020-0468","article-title":"Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy","volume":"32","author":"Pratama","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol [Internet]"},{"issue":"9","key":"10.1016\/j.ijtb.2023.04.006_bib23","first-page":"61","article-title":"Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers","author":"Garrabou","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2023.04.006_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2156-5-26","article-title":"Most of the extant mtDNA boundaries in South and Southwest Asia were likely shaped during the initial settlement of Eurasia by anatomically modern humans","volume":"5","author":"Metspalu","year":"2004","journal-title":"BMC Genet"},{"issue":"9","key":"10.1016\/j.ijtb.2023.04.006_bib25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmi.2019.06.020","article-title":"Does linezolid have a role in shortening treatment of tuberculosis?","volume":"25","author":"Yew","year":"2019","journal-title":"Clin Microbiol Infection"},{"issue":"2","key":"10.1016\/j.ijtb.2023.04.006_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.01684-21","article-title":"Early bactericidal activity of delpazolid (LCB01-0371) in patients with pulmonary tuberculosis","volume":"66","author":"Kim","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijtb.2023.04.006_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115714","article-title":"In\u00a0vitro activity of tedizolid and linezolid against multidrug-resistant Mycobacterium tuberculosis: a comparative study using microdilution broth assay and genomics","volume":"103","author":"Aono","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijtb.2023.04.006_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.arbres.2022.07.012","article-title":"Rapid diagnosis of XDR and pre-XDR TB: a systematic review of available tools","author":"Saderi","year":"2022","journal-title":"Arch Bronconeumol [Internet]"},{"issue":"10","key":"10.1016\/j.ijtb.2023.04.006_bib29","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med [Internet]"},{"issue":"7","key":"10.1016\/j.ijtb.2023.04.006_bib30","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkab075","article-title":"Saliva-based linezolid monitoring on a mobile UV spectrophotometer","volume":"76","author":"Kim","year":"2021","journal-title":"J Antimicrob Chemother [Internet]"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001957072300063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001957072300063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:25:07Z","timestamp":1762176307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001957072300063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":31,"alternative-id":["S001957072300063X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2023.04.006","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2023.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}